Clinical Trial

Trial of the Efficacy and Safety of Use of Drug Product Reamberin® for Pathogenetic Therapy of Viral Enteric Infection in Children Aged 1-6 Years Old

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 15, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
To assess the efficacy and safety of use of drug product Reamberin® solution for infusion, 1.5 % (Scientific Technological Pharmaceutical Firm "POLYSAN") for pathogenetic therapy of viral enteric infection in children aged 1-6 years old in routine clinical practice. Trial population: children of both sexes at the age of 1-6 years old inclusive with viral enteric infection.
Trial Details
NCT Number NCT07066540
Lead Sponsor POLYSAN Scientific & Technological Pharmaceutical Company
Conditions Viral Enteric Infection
Enrollment 300 participants
Start Date 2024-08-01
Primary Completion 2026-06 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-07-15